Vir Biotechnology. has filed a patent for antibodies and fragments that target the F-protein of metapneumovirus (MPV), neutralizing infection. The invention includes nucleic acids, cells expressing the antibodies, and methods for detection, diagnosis, treatment, and prevention of MPV. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of January 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for detecting, treating, and preventing metapneumovirus infection
See Also:
A recently filed patent (Publication Number: US20240034772A1) discloses a novel antibody or antigen-binding fragment that specifically binds to the F-protein of metapneumovirus (MPV). The antibody is designed to target the pre-fusion F protein of MPV, showing a higher binding affinity compared to the post-fusion F protein. Additionally, the antibody is capable of neutralizing MPV infection across different subgroups (A1, A2, B1, and B2). The patent claims cover various sequences of heavy and light chain complementarity-determining regions (CDRs) that exhibit high sequence identity with specific amino acid sequences, ensuring the antibody's specificity and efficacy in targeting MPV.
Furthermore, the patent includes claims related to the composition of the antibody, specifying requirements for sequence identity in the CDR regions, as well as the type of antibody (e.g., IgG type) and potential modifications to enhance its binding capabilities. The patent also extends to nucleic acid molecules encoding the antibody, vectors containing these nucleic acids, and cells expressing the antibody. The disclosed antibody and related compositions are intended for use as a medicament for prophylaxis or treatment of MPV infection, as well as for diagnostic purposes to detect MPV antigens. Overall, the patent presents a promising development in the field of antibody therapeutics for combating MPV infections, offering a potential avenue for improved treatment options and diagnostic tools in the future.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
